Pricing, Reimbursement and Launch Planning Strategy
Objectives: To develop pricing and reimbursement (P&R) strategy, assess pre-approval use possibilities and identify any specific local issues
Therapy Area: Orphan inherited disease (mucopolysaccharidosis)
Client: USA Biopharmaceutical company
Product/Technology: Drug
Scope: 15 European countries
Our Workplan: Developed product profile and discussion guide followed by Key Opinion Leader (KOL) and payer discussions in each territory
Project Duration: 12 weeks
Outcome: Provided report and summary presentation of findings/recommendations including in-market and international pricing strategy, optimal launch sequence, reimbursement data needs, identifying main likely treatment centres and markets where a pre-approval use availability was advocated. Full international team attended results presentation meeting.
Case Studies
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
